Cargando…

RE: Praluent (Alirocumab)-Induced Renal Injury

Detalles Bibliográficos
Autores principales:	Rosenson, Robert S., Larrey, Dominique, Waters, David D., Olsson, Anders G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844452/ https://www.ncbi.nlm.nih.gov/pubmed/28974137 http://dx.doi.org/10.1177/0897190017734429

Ejemplares similares

Effects of a short-term alirocumab administration on the aortic stiffness: preliminary results
por: Mauro, Feola, et al.
Publicado: (2019)

LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials
por: Ginsberg, Henry N., et al.
Publicado: (2021)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

Re: Erythropoietin Ameliorates Oxidative Stress and Tissue Injury following Renal Ischemia/Reperfusion in Rat Kidney and Lung
por: Rafieian-Kopaei, Mahmoud, et al.
Publicado: (2013)

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
por: Bays, Harold E., et al.
Publicado: (2018)

Re: Protective Role of Silymarin and Deferoxamine against Iron Dextran - Induced Renal Iron Deposition in Male Rats
por: Baradaran, Azar, et al.
Publicado: (2014)

Re: Heparin-induced thrombocytopenia – Type 2
por: Yagnik, Vipul D.
Publicado: (2011)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
por: Stroes, Erik, et al.
Publicado: (2016)

Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation
por: Meunier, Lucy, et al.
Publicado: (2019)

Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Re: Renal Artery Stenting is no Longer Indicated After ASTRAL: Pros and Cons
por: Reekers, Jim A.
Publicado: (2011)

Re: Incidence and treatment of malignant tumors of the genitourinary tract in renal transplant recipients
por: Floyd, Michael S., et al.
Publicado: (2019)

Re: Serum tissue factor as biomarker for renal clear cell carcinoma: a comment
por: Joob, Beuy, et al.
Publicado: (2018)

Re: Ureteric injury during gynaecological surgery – Lessons from 20 cases in Canada.
por: Jacob, GP, et al.
Publicado: (2021)

RE: Distinguishing between Renal Cell Carcinoma and Fat Poor Angiomyolipoma in Diffusion-Weighted Imaging
por: Sivrioglu, Ali Kemal, et al.
Publicado: (2017)

Synthetic cannabinoids and renal injury
por: Alp, Alper
Publicado: (2015)

Renal injury in obese children
por: Kawada, Tomoyuki
Publicado: (2019)

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Mortality Benefit of Alirocumab: A Bayesian Perspective
por: Labos, Christopher, et al.
Publicado: (2019)

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial
por: Goodman, Shaun G., et al.
Publicado: (2023)

Re: Neural injury after use of vasopressin and adrenaline during porcine cardiopulmonary resuscitation
por: Rottenberg, Eric M
Publicado: (2015)

Toxic renal injury at a glance
por: Gheshlaghi, Farzad
Publicado: (2012)

Re-assessment of re-warming for out-of-hospital births
por: Jones, Peter, et al.
Publicado: (2020)

Anti-Thymocyte Globulin Induced Acute Lung Injury in a Case of Renal Allograft Recipient
por: Gupta, Nimish, et al.
Publicado: (2021)

Re: Antibiotic prophylaxis prior to urodynamic study in patients with traumatic spinal cord injury. Is there an indication?
por: Floyd, Michael S, et al.
Publicado: (2019)

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)
por: East, Cara, et al.
Publicado: (2022)

Response to Stutz et al. re: “Management of Suspected Bladder Injury and Capsular Perforation After Holmium Laser Enucleation of the Prostate”
por: Lwin, Aye, et al.
Publicado: (2018)

Re-biopsy in lupus nephritis: Re-biópsia em nefrite lúpica
por: Husein, Raida, et al.
Publicado: (2014)

Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury
por: Asai, Hiroaki, et al.
Publicado: (2014)

Re: Maxillary Artery Pseudoaneurysm as a Complication of Maxillofacial Injuries: Report of three cases and literature review
por: Al Shaqsi, Sultan, et al.
Publicado: (2020)

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
por: White, Harvey D, et al.
Publicado: (2019)

Alirocumab after acute coronary syndrome in patients with a history of heart failure
por: White, Harvey D, et al.
Publicado: (2021)

RE: Proximal bulbar periurethral abscess
por: Blaschko, Sarah D., et al.
Publicado: (2015)

REPLY BY THE AUTHORS: Re: Antibiotic prophylaxis prior to urodynamic study in patients with traumatic spinal cord injury. Is there an indication?
por: da Silva, Marcello Torres, et al.
Publicado: (2019)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Letter to the Editor re: Biglari et al. (2016)
por: Zura, Robert, et al.
Publicado: (2016)

RE: Hemopericardium Following Acupuncture?
por: Kim, Tae-Hun, et al.
Publicado: (2011)

Re: Misconceptions Are “So Yesterday!”
por: Crowther, Gregory J., et al.
Publicado: (2014)

RE: Percutaneous Retroperitoneal Access
por: Battal, Bilal, et al.
Publicado: (2014)

Re: Academic integrity and plagiarism
por: Joob, Beuy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b5d65je0pjkq5n47vofh35s3r0